Tags : (lumacaftor + ivacaftor)


Vertex Signs an Access Agreement with Scottish Government for Orkambi

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex will collect real-world data on the combination therapies which will support future regulatory submission to the Scottish Medicines Consortium (SMC) following the 5yrs. access agreement Orkambi is a combination therapy used to […]Read More